US EditionUS appeals court to weigh reviving cases over Tylenol and autism
The U.S. Court of Appeals for the Second Circuit questioned the dismissal of expert testimony in lawsuits linking prenatal acetaminophen use to autism and ADHD.
- On Monday, the U.S. Court of Appeals for the Second Circuit heard oral arguments that suggested it may revive the multidistrict litigation in the Southern District of New York involving 600 lawsuits against Kenvue, Walmart, and CVS linking prenatal acetaminophen to autism and ADHD.
- The 2023 ruling excluded all five plaintiffs' experts, prompting an appeal, as plaintiffs allege Kenvue and Tylenol's former parent, Johnson & Johnson, deceptively marketed Tylenol as safe, with claims echoed in Paxton's October 28 filing.
- Judge Gerard Lynch pressed the district-court rationale during oral arguments, questioning its dismissal as nonsense while researchers said no firm evidence links acetaminophen to autism and Kenvue maintained Tylenol's safety.
- State-Court rulings produced early setbacks for the Texas Attorney General as Panola County District Judge LeAnn Rafferty denied Ken Paxton's request to bar Kenvue's safety claims and block $400 million in dividends.
- Broader public-health guidance and liability hinge on the federal appeals court's decision, amid scientific disagreement and claims amplified by public figures, including President Trump and Robert F. Kennedy Jr., on the $400 million dividend dispute.
22 Articles
22 Articles
Court Considers Reopening Tylenol Cases
A federal appeals court is weighing whether to revive hundreds of lawsuits filed by parents who claimed their child’s autism or ADHD was linked to Tylenol. The cases were dismissed in 2023 after U.S. District Judge Denise Cote ruled that the “unstructured approach adopted by the plaintiffs’ experts permitted cherry-picking, allowed a results-driven analysis, and obscured the complexities, inconsistencies, and weaknesses in the underlying data.” …
Federal judges weigh reviving court cases linking Tylenol to autism
Tylenol is displayed for sale at a CVS Pharmacy on November 03, 2025 in Austin, Texas. (Brandon Bell/Getty Images) (NEW YORK) — A federal appeals court is deciding whether to revive more than 500 lawsuits filed by parents who claimed their children’s autism or attention deficit hyperactivity disorder (ADHD) was caused by prenatal exposure to Tylenol. The lawsuits were dismissed in December 2023 by U.S. District Judge Denise Cote after finding th…
‘He’s Not Doing Nonsense’: Federal Appeals Panel Receptive to Tossed Plaintiffs’ Expert on Tylenol and Autism
In oral arguments on Monday, the U.S. Court of Appeals for the Second Circuit criticized aspects of U.S. District Judge Denise Cote’s 2023 ruling tossing all five plaintiffs’ experts tying acetaminophen to autism and ADHD.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
